Andrew Saik's Insider Trades & SAST Disclosures
Andrew Saik's most recent trade in Arvinas Inc was a trade of 74,960 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 13, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Andrew Saik.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arvinas Inc | Andrew Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 74,960 | 74,960 | - | - | Stock Option (right to buy) | |
| Arvinas Inc | Andrew Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 49,092 | 110,501 (0%) | 0% | 0 | Common Stock | |
| Milestone Pharmaceuticals Inc | Andrew Saik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Milestone Pharmaceuticals Inc | Andrew Saik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Arvinas Inc | Andrew Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 94,418 | 94,418 | - | - | Stock Option (right to buy) | |
| Arvinas Inc | Andrew Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 61,409 | 61,409 (0%) | 0% | 0 | Common Stock | |
| Intercept Pharmaceuticals Inc | Andrew Saik | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.74 per share. | 21 Jun 2023 | 908 | 69,173 (0%) | 0% | 11.7 | 10,660 | Common Stock |
| Intercept Pharmaceuticals Inc | Andrew Saik | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.19 per share. | 21 Mar 2023 | 909 | 70,081 (0%) | 0% | 14.2 | 12,899 | Common Stock |
| Intercept Pharmaceuticals Inc | Andrew Saik | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 24,000 | 24,000 | - | - | Option to Purchase Common Stock | |
| Intercept Pharmaceuticals Inc | Andrew Saik | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 14,700 | 70,990 (0%) | 0% | 0 | Common Stock | |
| Intercept Pharmaceuticals Inc | Andrew Saik | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.37 per share. | 31 Dec 2022 | 718 | 56,290 (0%) | 0% | 12.4 | 8,882 | Common Stock |
| Intercept Pharmaceuticals Inc | Andrew Saik | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.43 per share. | 21 Dec 2022 | 908 | 57,008 (0%) | 0% | 13.4 | 12,194 | Common Stock |
| Intercept Pharmaceuticals Inc | Andrew Saik | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.85 per share. | 21 Sep 2022 | 908 | 57,916 (0%) | 0% | 14.9 | 13,484 | Common Stock |
| Intercept Pharmaceuticals Inc | Andrew Saik | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.48 per share. | 21 Jun 2022 | 3,632 | 58,824 (0%) | 0% | 12.5 | 45,327 | Common Stock |
| Intercept Pharmaceuticals Inc | Andrew Saik | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 17,600 | 17,600 | - | - | Option to Purchase Common Stock | |
| Intercept Pharmaceuticals Inc | Andrew Saik | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 10,300 | 62,456 (0%) | 0% | 0 | Common Stock | |
| VYNE Therapeutics Inc | Andrew Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 3.36 per share. | 28 May 2021 | 3,017 | 116,468 (0%) | 0% | 3.4 | 10,130 | Common Stock |
| VYNE Therapeutics Inc | Andrew Saik | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.84 per share. | 31 Mar 2021 | 762 | 113,451 (0%) | 0% | 6.8 | 5,212 | Common Stock |
| VYNE Therapeutics Inc | Andrew Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 68,162 | 68,162 | - | - | Stock Options | |
| VYNE Therapeutics Inc | Andrew Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 29,213 | 114,213 (0%) | 0% | 0 | Common Stock | |
| VYNE Therapeutics Inc | Andrew Saik | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.46 per share. | 08 Sep 2020 | 40,000 | 340,000 (1%) | 0% | 1.5 | 58,480 | Common Stock |
| VYNE Therapeutics Inc | Andrew Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2020 | 250,000 | 300,000 (1%) | 1% | 0 | Common Stock | |
| VYNE Therapeutics Inc | Andrew Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2020 | 250,000 | 250,000 | - | - | Stock Options | |
| VYNE Therapeutics Inc | Andrew Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2020 | 100,000 | 100,000 | - | - | Stock Options | |
| VYNE Therapeutics Inc | Andrew Saik | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2020 | 50,000 | 50,000 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges